Not yet recruiting
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer
NCT05038098· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Naruhiko Ikoma
Not yet recruiting
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
NCT07511036· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Rodabe N Amaria, MD
Recruiting
Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
NCT07377006· M.D. Anderson Cancer Center· Source
Contact: Debanjan Pain
Recruiting
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
NCT06769126· Phase 2· SWOG Cancer Research Network· Source
Contact: Carl M. Gay (principal investigator)
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105· Phase 1· Fate Therapeutics· Source
Contact: Principle Investigator
Recruiting
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
NCT07407920· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Vicente Valero, MD
Recruiting
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
NCT05873192· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Amado Zurita-Saavedra, MD
Recruiting
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
NCT04199026· M.D. Anderson Cancer Center· Source
Contact: Joseph A. Ludwig
Active, not recruiting
Comprehensive Assessment of Cancer Theranostic Response
NCT06815354· AIQ Solutions· Source
Recruiting
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243· Phase 3· SWOG Cancer Research Network· Source
Contact: Paul Corn (principal investigator)
Recruiting
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
NCT06410209· Phase 2· Children's Oncology Group· Source
Contact: Najat C. Daw (principal investigator)
Recruiting
Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment
NCT05041140· M.D. Anderson Cancer Center· Source
Contact: Ajay Sheshadri
Recruiting
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939· Phase 3· SWOG Cancer Research Network· Source
Contact: Jing Christine Ye (principal investigator)
Active, not recruiting
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
NCT05961709· Phase 2· M.D. Anderson Cancer Center· Source
Recruiting
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
NCT06066437· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Marisa Lozano
Recruiting
A Comparison of Healthcare Provider and Caregiver Perception of Discomfort in Advanced Cancer Patients Who Have a Hypoactive Delirium
NCT05837039· M.D. Anderson Cancer Center· Source
Contact: Micheal Tang, MD
Recruiting
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
NCT06108232· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Dai Chihara, M D, PhD
Recruiting
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
NCT03594630· Early phase 1· M.D. Anderson Cancer Center· Source
Contact: George J. Chang
Recruiting
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT05231122· Phase 2· Roswell Park Cancer Institute· Source
Contact: Amir A. Jazaeri
Active, not recruiting
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
NCT06113302· Phase 2· M.D. Anderson Cancer Center· Source
Recruiting
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
NCT06105554· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Robert Orlowsky, M D
Recruiting
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
NCT05985954· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Christine Parseghian, MD
Recruiting
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
NCT05967182· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Hop Tran Cao, MD
Active, not recruiting
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT06053658· Phase 2· M.D. Anderson Cancer Center· Source
Recruiting
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06045247· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Dai Chihara, M D
Recruiting
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT05910801· Phase 2· Academic and Community Cancer Research United· Source
Contact: Debbie Stroughter
Active, not recruiting
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
NCT05922904· Phase 2· M.D. Anderson Cancer Center· Source
Active, not recruiting
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
NCT05722327· Phase 1· M.D. Anderson Cancer Center· Source
Recruiting
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
NCT06085664· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Sumit K. Subudhi, MD, PHD
Recruiting
A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
NCT05947838· M.D. Anderson Cancer Center· Source
Contact: Michael White, MD
Recruiting
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
NCT06066359· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Muzaffar Qazilbash, M D
Recruiting
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
NCT06004336· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Chad Tang, MD
Recruiting
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
NCT06109870· M.D. Anderson Cancer Center· Source
Contact: Jane Montealegre, M. D.
Recruiting
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
NCT05834244· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Abhishek Maiti, MD
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988· Phase 1/2· Volastra Therapeutics, Inc.· Source
Contact: Ecaterina Dumbrava, MD
Recruiting
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387· Phase 3· SWOG Cancer Research Network· Source
Contact: Jing Christine Ye (principal investigator)
Active, not recruiting
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT05922930· Phase 1/2· M.D. Anderson Cancer Center· Source
Active, not recruiting
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
NCT05621668· Phase 1· M.D. Anderson Cancer Center· Source
Recruiting
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
NCT06036810· M.D. Anderson Cancer Center· Source
Contact: Larissa Meyer, M D
Active, not recruiting
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT05761951· Phase 2· M.D. Anderson Cancer Center· Source
Active, not recruiting
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
NCT05704634· Phase 1· M.D. Anderson Cancer Center· Source
Recruiting
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
NCT05776979· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Muzaffar Qazilbash, MD
Recruiting
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
NCT06006273· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Fiorela Hernandez Tejada, MD
Active, not recruiting
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
NCT05836870· Phase 3· M.D. Anderson Cancer Center· Source
Recruiting
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT05819892· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Pamela Soliman, MD
Recruiting
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
NCT05645718· Phase 2· M.D. Anderson Cancer Center· Source
Contact: David McCall, MD
Recruiting
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
NCT05636111· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Shannon Westin, MD
Recruiting
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
NCT05674396· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Jay Reddy, MD, PHD
Active, not recruiting
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
NCT05672459· Phase 1/2· M.D. Anderson Cancer Center· Source
Active, not recruiting
Reminder Messages for Lung Cancer Screening
NCT05952778· M.D. Anderson Cancer Center· Source
Showing 50 of 498.